IsoPlexis Announces Preliminary Unaudited Revenue For The Full Year Ended Dec 31, 2022 Total Revenue To Be In The Range Of $16.6M-$16.8M, Down 3%-4% YoY; Q4 Results Were Lower Than Expected Primarily Due To The Timing Of Customer Orders For Instruments
IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended
